The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

The most frequent mechanism of resistance after 1st/2nd-generation (G) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is secondary point mutation Thr790Met (T790M) in EGFR. Afatinib followed by osimertinib (Afa group) may provide better outcomes for T790M-positive non-smal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Tamiya, Motohiro, Tamiya, Akihiro, Okamoto, Norio, Taniguchi, Yoshihiko, Nishino, Kazumi, Atagi, Shinji, Hirashima, Tomonori, Imamura, Fumio, Kumagai, Toru, Suzuki, Hidekazu
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099906/
https://ncbi.nlm.nih.gov/pubmed/33953280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-89006-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars